This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. mutations could not be retrieved in related public databases and were considered to be novel. Among patients with ovarian cancer, 115 deleterious mutations were identified in 429 patients (48.6%) with significant enrichment for a family history of breast or ovarian cancer syndrome (P < .05). In the breast cancer subgroup, 31 deleterious mutations were identified in 261 patients. Besides BRCA1 (8; 25.8%) and BRCA2 (11; 35.5%), the most frequently occurring genes, an additional 12 deleterious mutations (38.7%) were found in seven other susceptibility genes. Higher mutation incidence (57.9%) was observed in subjects with histories of breast and ovarian cancer. Our results highlighted the genetic heterogeneity of HBOC and the efficiency of a multigene panel in carrying out risk assessment.
| INTRODUC TI ON
Breast and ovarian cancers fiercely impact health of Chinese women as well as their families. 1, 2 As is known, these two diseases are heritable. Inherited mutations of BRCA1 and BRCA2 are pathogenetic in a majority of HBOC patients. 3, 4 In addition to BRCA1/2, genetic alterations of other HR genes (ATM, BRIP1, CHEK2, RAD50, RAD51C) are also associated with HBOC. [5] [6] [7] [8] Moreover, research has indicated that mutations in the susceptibility genes (TP53, PTEN, STK11, and CDH1) were also associated with hereditary cancer syndromes such as Li-Fraumeni syndrome, Cowden syndrome, Peutz-Jeghers syndrome, and hereditary diffuse gastric cancer syndrome. [9] [10] [11] [12] [13] Moreover, congenital aberrations in mismatch repair genes also contributed to the onset of epithelial ovarian cancer. For instance, germline MSH6 alterations were proven to increase the risk of ovarian cancer.
14 In addition to genetic counseling and risk management, it has been widely shown that germline BRCA1/2 as well as other HR gene mutations may serve as prognostic markers for several tumor types including breast and ovarian cancers. Therapeutically, BRCA1/2 and HR mutations ought to be good predictors of platinum-based (neo) adjuvant regimens for patients with triple-negative breast cancer or advanced epithelial ovarian cancer. Recently, several phase 3 clinical trials indicated germline BRCA1/2 pathogenic mutations well predicated the response to PARP inhibitors of patients with advanced ovarian carcinomas as well as patients with HER2-negative breast cancer. 15, 16 Traditional genetic testing methods, such as PCR-based assay and the DGGE mutation scanning system, have been applied to detect BRCA1/2 widely in China. 8, 17 However, BRCA1/2 are high-risk tumor suppressor genes without significant mutation hotspots; as a result, some mutations would be missed by conventional approaches. Results
from recent studies confirmed that next-generation sequencing (NGS)
showed multiple advantages in cancer genetic testing in terms of time and cost-effectiveness. [18] [19] [20] However, there are insufficient related reports on HBOC patients in the Chinese population.
To investigate the mutation frequency among individuals with a suspected HBOC risk in the Chinese population, we used multigene testing to show the distribution and prevalence of deleterious germline mutations among 882 patients with suspected HBOC risk in 21 HBOC hereditary susceptibility genes. Our results evaluated the benefits and limitations of multigene panel testing and provided insights into choosing appropriate multigene tests to assess the risk of hereditary cancer. 
| MATERIAL S AND ME THODS

| Participants
| Sequencing data analysis and mutation calling
Raw fastq data generated by the sequencer were first filtered by SOAPnuke to exclude low-quality reads. Clean reads were then aligned to the reference human genome (UCSC hg19) using the Burrows-Wheeler Aligner (BWA) ALN algorithm. Single nucleotide variants (SNV) were detected by the GATK Unified Genotyper.
Small insertions and deletions (InDels) were called using GATK
HaplotypeCaller. Copy number variants (CNV) were called using read-depth analysis. All the above variants were further filtered by quality depth, strand bias, mapping quality, and reads position. 
| Data interpretation
Interpretation was focused on variants in 21 selected susceptibility genes in HBOC ( 
| RE SULTS
| Participant characteristics
A total of 1175 individuals were referred to our clinical test center for Oseq-BRCA multigene testing, from which 882 participants were included in our study based on NCCN guidelines ( Figure 1 ).
Demographics for these 882 subjects are shown in 
| Deleterious mutations identified in this cohort
Exons and splice sites of 21 HBOC susceptibility genes were ex- In the breast cancer-only subgroup, 31 deleterious mutations were identified in 261 patients (Table 3) . Most mutations occurred in BRCA1 (8; 3.07%) and in BRCA2 (11; 4.21%). An additional 12 mutations (13.9%) were found in seven other susceptibility genes ( Figure 3B ). Deleterious BRCA1 mutations consisted of eight truncating (2 deletion, 2 frameshift, 2 nonsense, and 2 splice) mutations.
Deleterious BRCA2 mutations were 11 truncating mutations (9 frameshift, 2 nonsense). Among the other HR pathway genes, mutations were most commonly found in CHEK2 (n = 5; 1.92%) and BRIP1
(n = 2; 0.77%). In addition, mutations were also observed in RAD51C, PALB2, and MRE11A in one individual per gene. Only one Lynch syndrome gene mutation was identified in PMS1 in the breast cancer subgroup. Among the other highly penetrant genes, mutations were found in TP53 (n = 1; 0.38%) whereas no mutations were identified in STK11, PTEN, and CDH1.
In the ovarian cancer-only subgroup (n = 429), 115 deleterious mutations were identified in 113 individuals (Table 3) . Of these, 66 and MSH6 (n = 1), accounting for 3.5% of all mutations in the ovarian cancer subgroup. Among the other highly penetrant genes, mutations were found in TP53 (n = 1; 0.23%) and STK11 (n = 1; 0.23%).
In the subgroup of subjects with disease histories of both breast and ovarian cancer (n = 19) (Table 3) , a higher frequency of mutation rate was observed. Eleven (57.9%) subjects had a mutation, of which 10 had a mutation in BRCA1, and one had a MUTYH mutation ( Figure 3D ).
Furthermore, 173 subjects did not have a cancer diagnosis but had a family history of cancer. In this subgroup, 19 mutations were identified in 21 cancer susceptibility genes with a prevalence of 10.98% (Table 3) in which 10 were mutations in BRCA1/2 genes, two
one in RAD51C, and one in MUTYH ( Figure 3E ). Interestingly, in this subgroup, the proportion of missense mutations was significantly higher than in other subgroups ( Figure 3F ). No mutations were found in PALB2, RAD50, STK11, TP53, MSH2, MSH6, and PMS1 genes.
| Recurrent mutations, founder mutations, and novel mutations
In our cohort, recurrent mutations (n ≥ 3) were found in BRCA1 p.Ile1824AspfsX3, CHEK2 p.His371Tyr, BRCA1 p.Glu1257GlyfsX9, and BRCA2 p.Ser2670Leu (Table S1 ). BRCA1 p. 
| Variants of uncertain significance
The VUS rate in our cohort was 38.55% (n = 340), and 406 VUS mutations (339 missense, 58 splice, four in-frame, two frameshift, two duplication, one deletion) were detected in 882 individuals.
VUS mutations were most prevalent in ATM (n = 53), followed by (Table S2) , which can provide a basis for further analysis in subsequent studies.
| Mutation frequency in subgroups with different family histories and ages at diagnosis
The deleterious mutation rate for each subgroup according to age at diagnosis is detailed in Table 4 . In the breast cancer-only subgroup, mean age at diagnosis was 39 among mutation-positive probands and 40 among mutation-negative probands (P = .66). In the ovarian 
TA B L E 3 Frequency of mutations by personal cancer history
cancer-only cohort, average age at diagnosis was 53 among mutationpositive probands and 54 among mutation-negative probands (P = .90).
In the breast and ovarian cancer cohorts, age at diagnosis was slightly older among mutation-negative individuals compared to those positive for a mutation; however, the difference was not significant (P = .41) ( Table 4) . We also evaluated whether patient subjects with deleterious (Table 5) . Among breast cancer patients, no significant association was identified between mutations and family history of either breast cancer or ovarian cancer. However, among ovarian cancer patients, individuals with mutations were more likely to have a family history of either breast or ovarian cancer (P < .05) ( Table 5 ). subjects had a deleterious mutation, and 21.6% of deleterious mutations were in genes other than BRCA1 and BRCA2. The positive rate for the ovarian group was 26.81%, which was higher than for the breast cancer group (11.88%). Moreover, the mutation frequency of the BRCA gene in 173 subjects who were recruited based on family cancer history was significantly higher than that in the healthy population reported by a previous study (5.78% vs.
| D ISCUSS I ON
F I G U R E 4 Distribution of deleterious mutations detected in (A) BRCA1 and (B)
BRCA2 genes. Pins represent mutation position. Number represents the number of samples with the mutation (unmarked represents 1). Green bars represent deletion locations, and each segment represents a sample. The figure was created using ProteinPaint. *termination codon according the HGVS mutation nomenclature guidelines. https ://varno men.hgvs.org/recom menda tions/ gener al/; † novel mutation; ‡ Chinese founder mutation 0.38%), 23 indicating the validity of the inclusion criteria. Our study is distinguished from other studies in the following ways. First, our large-size cohort is recruited from multiple general hospitals across China which is a representative population for the target population in China. The prevalence of mutations in this population was rarely reported in previous studies. In addition, our cohort was selected according to the NCCN guidelines, including breast cancer patients, ovarian cancer patients, and high-risk volunteers.
Our results reflect the mutation frequency in individuals defined by the guidelines and have great clinical practical significance.
In the breast cancer-only subgroup, the prevalence of BRCA1
and BRCA2 deleterious mutations were 3.07% and 4.21%, respectively. In a previous Chinese population-based study, Sun et al 24 reported that BRCA1/2 deleterious mutation frequencies were 4.24% and 6.60% in an early-onset breast cancer cohort and in a familial breast cancer cohort, respectively, which is similar to our subgroup and those observed in other studies in China. 25, 26 However, the prevalence of BRCA1/2 deleterious variants in breast cancer in other countries ranges from 9.3% to 18%. In the subgroup of subjects with a diagnosis of both breast and ovarian cancer, high deleterious mutation rates (52.63% and 5.26%)
were observed in BRCA1 and MUTYH. Kwong et al 37 (2018, n = 20) reported that the prevalence of mutation Chinese patients with breast cancer complicated with ovarian cancer were 40% and 20%
for BRCA1 and BRCA2, respectively. Walsh et al 32 reported that the frequencies of BRCA1 and BRCA2 mutation were 38.71% and 22.58%, and three additional subjects carried BRIP1, CHEK2, and MRE11A mutations, respectively. It seems that the frequency of BRCA1 mutations in this subgroup is higher than in the group carrying the BRCA2 mutation; in particular, the BRCA1 p.I1824Dfs*3 mutation was found in two patients. Given the limited sample size, more evidence is needed to support this assumption.
The rate of VUS in a similar multigene panel study (27 genes) was 32.7%, in which the authors used a panel with fewer genes but with BRCA1/2 included. 38 Indeed, VUS rate in our cohort was 38.55%, which is slightly higher than the results of previous study. It is possible that the incidence of breast cancer and ovarian cancer in the Chinese population is lower than that in Caucasians, and the variants are relatively sporadic. ATM has the most frequent VUS detected due to the long transcript length. When we normlized the length of coding sequence (CDS) to make comparisons, it shows that RAD51C has the greatest number of VUS in per 1000 bases, up to 14.15 (Table S3 ). According to the NCCN guidelines, RAD51C specifically increases the risk of ovarian cancer. In our ovarian cancer patients, only one deleterious mutation of RAD51C was detected, which is relatively low compared with previous populations. 39 This may be due to the lack of reports on RAD51C mutation in the Chinese population.
Identification of deleterious variants in cancer susceptibility genes allows us to find eligible patients for surveillance screening, and it may also provide targeted therapy and prevention strategies not available in the management guidelines, whereas mutations in these genes were found in 2.60% of subjects. When encountering these mutations, it is a big challenge for clinicians. It is necessary to combine the family history and personal history to make a medical decision. Therefore, guidelines recommend that multigene testing is ideal in the context of professional genetic expertise for pre-and post-test counseling.
In conclusion, we reported the successful utility of multiple gene We would like to thank the patients and their families for their participation and support of our study. 
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